Ann: Bod expands medicinal cannabis product suite, page-8

First 8 Last

mackum8

1,077 Posts.

06/03/19

02:08

Post #: 37664891

Originally posted by DrKnow: ↑
very simple - sales revenues

what seperates companies at the moment in MC / Hemp / CBD space is talking versus delivering revenues and EXL has delivered revenues

Their international comparison companies (charloettes web and CV Science ) have markets caps multiples well higher than their compaitive sales figures - so EXL caught up

Here is my numbers, I focus on revenues not income as this is a land grab market at the moment so brand building, advertising spend and revenue growth are the key factors to success in my opinion

THESE NUMBERS ARE MAYBE A few weeks out of date but the picture is clear:

ASX Code Company Mkt Cap Ratio (mkt cap / revenue) 03/2019 Quarterly Revenue from 4C 12/2018 09/2018
1 AGH ALTHEA 23.4 28.5
$82 $28
2 BDA BOD AUSTRALIA 45.0 5.9
$766 $141
3 ZLD ZELDA THERAPEUTICS 41.0

$0 $0
4 MXC MGC PHARMA 49.0 6.6
$744 $135
5 CPH CRESO PHARMA 55.0 25.1
$219 $170
6 MDC MEDLAB CLINICAL 87.0 6.9
$1,269 $1,222
7 AC8 AUSCANN 188.0

$0 $0
8 CAN CANN GROUP 297.0

$1 $2
9 EXL ELIXINOL 445.0 3.9
$11,334 $9,831
10

$14,415 $11,529
Expand
the management seem to be revenue driven, especillay George, they will not be afraid to take on products to drive revenue, so I’m pretty confident we will see a substantial growth this year.

BDA Price at posting: 43.5¢ Sentiment: Buy Disclosure: Held

3 Upvote

0 Great analysis

Top Stories

ASX Market Open: Bessent hype, Lebanon ceasefire hopes push Aus markets higher | November 26, 2024

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

There are more pages in this discussion • 4 more messages in this thread...

First 8 Last

Add BDA (ASX) to my watchlist

	ASX Code	Company	Mkt Cap	Ratio (mkt cap / revenue)	03/2019	Quarterly Revenue from 4C 12/2018	09/2018
1	AGH	ALTHEA	23.4	28.5		$82	$28
2	BDA	BOD AUSTRALIA	45.0	5.9		$766	$141
3	ZLD	ZELDA THERAPEUTICS	41.0			$0	$0
4	MXC	MGC PHARMA	49.0	6.6		$744	$135
5	CPH	CRESO PHARMA	55.0	25.1		$219	$170
6	MDC	MEDLAB CLINICAL	87.0	6.9		$1,269	$1,222
7	AC8	AUSCANN	188.0			$0	$0
8	CAN	CANN GROUP	297.0			$1	$2
9	EXL	ELIXINOL	445.0	3.9		$11,334	$9,831
10						$14,415	$11,529

Ann: Bod expands medicinal cannabis product suite, page-8

Top Stories

ASX Market Open: Bessent hype, Lebanon ceasefire hopes push Aus markets higher | November 26, 2024

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Featured News